HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
申请人:CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.
公开号:US20170253614A1
公开(公告)日:2017-09-07
A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.
The regioselective carbonylation of unactivatedC(sp3)–Hbonds of aliphatic amides, using 2-pyridinylmethylamine as a directing group in conjunction with Ru3(CO)12 as a catalyst is described. The presence of a 2-pyridinylmethylamine moiety in the amides is crucial for the success of the reaction. Although ethylene is not incorporated into the products, its presence is also essential for the reaction
HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
申请人:Miyaji Katsuaki
公开号:US20090253751A1
公开(公告)日:2009-10-08
Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided.
A compound represented by the formula (I) (wherein R
1
, R
2
, R
3
, L
1
, L
2
, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.
A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).